Ben Blanc 02:17 Yeah, thanks, Robert
This is likely further enhanced by an increase in GLP-1expressing L-cells in the gut mucosa [9, 16, 17], and gut mucosa hyperplasia that increases intestinal glucose disposal after RYGB [16]
Tirzepatide is not covered by insurance
Keane, S
Disclosures: Cara Mack: Nothing to Disclose, Alexander Miethke: Mirum Pharmaceutical Inc: Grant/Research Support, Mirum Pharmaceutical Inc: Consultant, Ipsen: Speaking and Teaching, Kieran Hawthorne: Nothing to Disclose, Lisa Henn: Murata Vios: Consultant, Simon Horslen: Nothing to Disclose, Shika Sundaram: Nothing to Disclose, Estella Alonso: Nothing to Disclose, Nitika Gupta: Nothing to Disclose, Binita Kamath: Mirum: Consultant, Mirum: Grant/Research Support, Albireo/Ipsen: Consultant, Albireo/Ipsen: Grant/Research Support, Audentes: Consultant 2353 OBETICHOLIC ACID FOR PRIMARY BILIARY CHOLANGITIS IN THE PREVENTION OF CLINICAL EVENTS: A MODELING STUDY USING REAL-WORLD DATA Zobair Younossi 1 Alexandra Ellis 2 Jackie Lee 3 Leona Bessonova 4 Radhika Nair 4 Elizabeth Potente 4 Robert Gish 5 , 1 The Global Liver Council, Center for Outcomes Research in Liver Disease, Washington, DC, USA, 2 Stratevi, Boston, Massachusetts, USA, 3 Stratevi, Santa Monica, California, USA, 4 Intercept Pharmaceuticals, Morristown, New Jersey, USA, 5 Robert G
